Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SoligenixSNGX +0.92%23 EV-to-EBIT is 0.06 as of Aug. 24, 2026. GuruFocus rates SNGX with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 377 Biotechnology companies, Soligenix ranks better than 96.29% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Soligenix's Enterprise Value for the quarter that ended in Jun. 2026 was $-0.94 Mil.
Soligenix's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soligenix EV-to-EBIT Related Terms
Soligenix EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Soligenix's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Soligenix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soligenix EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soligenix's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Soligenix's EV-to-EBIT falls into.
Soligenix's current Enterprise Value is $-0.70 Mil.
Soligenix's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soligenix (SNGX) has a EV-to-EBIT of 0.06 as of Aug. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Soligenix and its competitors. According to the industry distribution chart, Soligenix ranks #14 out of 377 companies in the Biotechnology industry, placing it in the top 3.7%.
Is Soligenix's EV-to-EBIT too high?
Soligenix's current EV-to-EBIT is 0.06. The Biotechnology industry median EV-to-EBIT is 16.02. Soligenix's value of 0.06 is 99.6% below this industry median. Based on the distribution chart, Soligenix ranks #14 out of 377 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Soligenix has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Soligenix's EV-to-EBIT compare to APVO and BCAB?
According to the Biotechnology industry distribution chart, Soligenix ranks #14 out of 377 companies for EV-to-EBIT. This places Soligenix in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.02. Soligenix's value of 0.06 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.02, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Soligenix's current EV-to-EBIT of 0.06 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Soligenix and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Soligenix's current EV-to-EBIT is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soligenix stock overvalued right now?
Soligenix (SNGX) has a current EV-to-EBIT of 0.06. The current EV-to-EBIT is 0.06 and 99.6% below the Biotechnology industry median of 16.02. Soligenix's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Soligenix (SNGX), the current EV-to-EBIT is 0.06 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
23GF Score
Get the complete analysis for SNGX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNGX has been successfully added to your 
